Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Survey of antenatal women's knowledge of maternal and fetal risks of tobacco smoking and acceptability of nicotine replacement products in pregnancy.

Griffiths AN, Woolley JL, Avasarala S, Roy M, Wiener JJ.

J Obstet Gynaecol. 2005 Jul;25(5):432-4.

PMID:
16183574
2.

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.

Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg SD, Lou Y, Moore KH, Woolley JL, Stein DS.

J Clin Pharmacol. 2001 Apr;41(4):386-96.

PMID:
11304895
3.

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW.

Drug Metab Dispos. 2001 May;29(5):754-60.

PMID:
11302944
4.

Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration.

de Serres M, Yeager RL, Dillberger JE, Lalonde G, Gardner GH, Rubens CA, Simkins AH, Sailstad JM, McNulty MJ, Woolley JL.

Stem Cells. 1999;17(6):316-26.

5.

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL.

Pharm Res. 1999 Aug;16(8):1206-12.

PMID:
10468021
6.

Atovaquone and proguanil hydrochloride: a review of nonclinical studies.

Pudney M, Gutteridge W, Zeman A, Dickins M, Woolley JL.

J Travel Med. 1999 May;6 Suppl 1:S8-12. Review.

7.

Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.

Hughes WT, Sillos EM, LaFon S, Rogers M, Woolley JL, Davis C, Studenberg S, Pattishall E, Freeze T, Snyder G, Staton S.

J Infect Dis. 1998 Apr;177(4):1046-56.

PMID:
9534981
8.
9.

A robotics-based liquid chromatographic assay for the measurement of atovaquone in plasma.

Studenberg SD, Long JD, Woolf JH, Bruner CJ, Wilson D, Woolley JL.

J Pharm Biomed Anal. 1995 Oct;13(11):1383-93.

PMID:
8634356
10.

High-performance liquid chromatographic assay for the measurement of atovaquone in plasma.

DeAngelis DV, Long JD, Kanics LL, Woolley JL.

J Chromatogr. 1994 Feb 11;652(2):211-9.

PMID:
8006106
11.

The disposition and metabolism of [14C]piritrexim in dogs after intravenous and oral administration.

Woolley JL, Deangelis DV, Grace ME, Liao SH, Crouch RC, Sigel CW.

Drug Metab Dispos. 1991 Nov-Dec;19(6):1139-46.

PMID:
1687022
12.

The disposition and metabolism of [14C]piritrexim in rats after intravenous and oral administration.

Woolley JL, Deangelis DV, Crouch RC, Shockcor JP, Sigel CW.

Drug Metab Dispos. 1991 May-Jun;19(3):600-8.

PMID:
1680625
13.

Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat.

Patel DK, Woolley JL Jr, Shcokcor JP, Johnson RL, Taylor LC, Sigel CW.

Drug Metab Dispos. 1991 Mar-Apr;19(2):491-7.

PMID:
1676660
14.

Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis.

Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, Yao JD, DeAngelis DV, Walton L, Woolley JL, Moellering RC Jr.

Antimicrob Agents Chemother. 1990 Sep;34(9):1792-4.

15.
16.

A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).

Weiss GR, Sarosy GA, Shenkenberg TD, Williams T, Clendeninn NJ, Von Hoff DD, Woolley JL, Liao SH, Blum MR.

Eur J Cancer Clin Oncol. 1989 Dec;25(12):1867-73.

PMID:
2632268
17.

Competitive protein binding assay for piritrexim.

Woolley JL Jr, Ringstad JL, Sigel CW.

J Pharm Sci. 1989 Sep;78(9):749-52.

PMID:
2585269
18.

Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma.

Myers RC, Lau BH, Kunihira DY, Torrey RR, Woolley JL, Tosk J.

Urology. 1989 Mar;33(3):230-5.

PMID:
2919485
19.
20.

Effect of the calcium entry blocker verapamil on renal ischemia.

Woolley JL, Barker GR, Jacobsen WK, Gingrich GA, Stewart SC, Briggs BA, Martin RD, Melashenko RA.

Crit Care Med. 1988 Jan;16(1):48-51.

PMID:
3338279
21.

Methapyrilene is a genotoxic carcinogen: studies on methapyrilene and pyrilamine in the L5178Y/TK +/- mouse lymphoma assay.

Turner NT, Woolley JL Jr, Hozier JC, Sawyer JR, Clive D.

Mutat Res. 1987 Nov;189(3):285-97.

PMID:
3670332
22.

Superiority of intravesical immunotherapy with Corynebacterium parvum and Allium sativum in control of murine bladder cancer.

Marsh CL, Torrey RR, Woolley JL, Barker GR, Lau BH.

J Urol. 1987 Feb;137(2):359-62.

PMID:
3806842
23.

Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase.

Sigel CW, Macklin AW, Woolley JL Jr, Johnson NW, Collier MA, Blum MR, Clendeninn NJ, Everitt BJ, Grebe G, Mackars A, et al.

NCI Monogr. 1987;(5):111-20.

PMID:
3431588
24.

Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma.

Lau BH, Woolley JL, Marsh CL, Barker GR, Koobs DH, Torrey RR.

J Urol. 1986 Sep;136(3):701-5.

PMID:
3735559
25.

Emission and transmission tomography of the brain in cerebrovascular disease.

Tsementzis SA, Hitchcock ER, Woolley JL.

Surg Neurol. 1984 Apr;21(4):385-90.

PMID:
6608161
26.
27.

Development of pharmacokinetic models for sulfonamides in food animals: metabolic depletion profile of sulfadiazine in the calf.

Woolley JL Jr, Sigel CW.

Am J Vet Res. 1982 May;43(5):768-74. No abstract available.

PMID:
7091837
28.

Pharmacokinetics of trimethoprim and sulfadiazine in the dog: urine concentrations after oral administration.

Sigel CW, Ling GV, Bushby SR, Woolley JL Jr, DeAngelis D, Eure S.

Am J Vet Res. 1981 Jun;42(6):996-1001.

PMID:
7283250
29.

II. Novel deaminated sulfadiazine metabolites in neonatal calf tissue, plasma, and urine following oral treatment of 14C-sulfadiazine.

Woolley JL Jr, Sigel CW, Wels CM.

Life Sci. 1980 Nov 17;27(20):1819-26. No abstract available.

PMID:
7464453
30.

Metabolism and disposition by the rat of 35S-sulfadiazine alone and in the presence of trimethoprim.

Woolley JL Jr, Sigel CW.

Drug Metab Dispos. 1979 Mar-Apr;7(2):94-9.

PMID:
38079
31.

Thin layer chromatographic screening method for sulfadiazine residues in calf tissues, plasma, and urine.

Woolley JL Jr, Murch O, Sigel CS.

J Assoc Off Anal Chem. 1978 May;61(3):545-9.

PMID:
649546
32.

Cranial isotopic section scanning.

Woolley JL, Williams B, Venkatesh S.

Clin Radiol. 1977 Sep;28(5):517-28.

PMID:
589903
33.

Lipid-soluble diaminopyrimidine inhibitors of dihydrofolate reductase.

Nichol CA, Cavallito JC, Woolley JL, Sigel CW.

Cancer Treat Rep. 1977 Jul;61(4):559-64.

PMID:
301777
34.

Specific TLC tissue residue determination of sulfadiazine following fluorescamine derivatization.

Sigel CW, Woolley JL Jr, Nichol CA.

J Pharm Sci. 1975 Jun;64(6):973-6.

PMID:
1133754
35.

Cerebral scintigraphy with a Nuclear Chicago 1206 high performance gamma camera.

Pexman JH, Woolley JL.

Br J Radiol. 1974 Jul;47(559):417-21. No abstract available.

PMID:
4368482
36.

An evaluation of static cerebral studies with a nuclear data (Selektronik) radicamera II.

Pexman JH, Woolley JL.

Br J Radiol. 1973 Sep;46(549):735. No abstract available.

PMID:
4726127

Supplemental Content

Loading ...
Support Center